Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20476197 | 1.00 | LMNA (0.48) | LMNAHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL11005625 | 0.92 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL11130007 | 0.92 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL11805820 | 0.92 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL1502818 | 0.92 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL11130016 | 0.92 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL11005612 | 0.92 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL4074100 | 0.89 | LMNA (0.41) | LMNAHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL5369513 | 0.89 | PPARG (0.42) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL5369516 | 0.89 | PPARG (0.42) | LMNAHSD17B10MEN1KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165940-A1 | METHODS OF TREATING CONDITIONS CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS | HOFFMAN TECHNOLOGIES LLC | 2023-06-01 | — | — | US | claimed |
| EP-4132561-A1 | METHODS OF TREATING CONDITIONS CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS | Hoffman Technologies LLC. (US) | 2023-02-15 | — | — | EP | claimed |
| EP-3681476-B1 | TRANSDERMAL FORMULATIONS | TYME INC (US) | 2022-09-14 | — | — | EP | claimed |
| WO-2021119096-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | TYME, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-20210169903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | TYME, INC. | 2021-06-10 | — | — | US | claimed |
| US-20210008214-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2021-01-14 | — | — | US | claimed |
| US-20200405680-A1 | TRANSDERMAL FORMULATIONS | TYME, INC. (US) | 2020-12-31 | — | — | US | claimed |
| EP-3681476-A1 | TRANSDERMAL FORMULATIONS | Tyme, Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| WO-2020112766-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-06-04 | — | — | WO | claimed |
| US-20200163952-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-05-28 | — | — | US | claimed |
| US-20190192663-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2019-06-27 | — | — | US | claimed |
| WO-2019055747-A1 | TRANSDERMAL FORMULATIONS | TYME, INC. (US) | 2019-03-21 | — | — | WO | claimed |
| EP-3237013-A1 | TRANSDERMAL FORMULATIONS | Hoffman, Steve (US) | 2017-11-01 | — | — | EP | claimed |
| US-20160199453-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2016-07-14 | — | — | US | claimed |
| US-20160193339-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2016-07-07 | — | — | US | claimed |
| WO-2016105530-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2023102134-A2 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230165940-A1 | METHODS OF TREATING CONDITIONS CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS | HOFFMAN TECHNOLOGIES LLC | 2023-06-01 | — | — | US | disclosed |
| EP-1506183-A1 | METHOD OF FORMING IRON HYDROXYPYRONE COMPOUNDS | Vitra Pharmaceuticals Ltd. (GB) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097627-A1 | METHOD OF FORMING IRON HYDROXYPYRONE COMPOUNDS | VITRA PHARMACEUTICALS LIMITED (GB) | 2003-11-27 | — | — | WO | disclosed |